Solriamfetol - Latest Advances

Evaluating solriamfetol interference in urine amphetamine immunoassays: a four-platform comparison.

Journal: Journal of analytical toxicology

Published: December 25, 2025

"Too small to succeed?" Rethinking efficacy claims in a solriamfetol trial for ME/CFS.

Journal: Journal of psychopharmacology (Oxford, England)

Published: December 01, 2025

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Published: October 07, 2025

Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials.

Journal: Expert opinion on pharmacotherapy

Published: September 23, 2025

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Journal: Journal of psychopharmacology (Oxford, England)

Published: September 17, 2025

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 24, 2025

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Journal: Postgraduate medicine

Published: May 06, 2025

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Journal: Sleep medicine

Published: April 17, 2025

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Journal: Sleep & breathing = Schlaf & Atmung

Published: April 09, 2025

Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis.

Journal: BMC neurology

Published: April 08, 2025

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Journal: CNS drugs

Published: April 03, 2025

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea

Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Published: March 30, 2025

Filters

Evaluating solriamfetol interference in urine amphetamine immunoassays: a four-platform comparison.

Evaluating solriamfetol interference in urine amphetamine immunoassays: a four-platform comparison.

"Too small to succeed?" Rethinking efficacy claims in a solriamfetol trial for ME/CFS.

"Too small to succeed?" Rethinking efficacy claims in a solriamfetol trial for ME/CFS.

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials.

Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials.

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database.

Drugs induced Raynaud's phenomenon and underlying mechanism: a disproportionality analysis from the WHO pharmacovigilance database.

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Solriamfetol for the treatment of excessive daytime sleepiness in participants with obstructive sleep apnea with different levels of adherence to primary OSA therapy: Subgroup analysis of a randomized clinical trial.

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Correction to: SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany.

Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis.

Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis.

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial.

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea

Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea